GlycoMimetics Inc (GLYC) - Net Assets
Based on the latest financial reports, GlycoMimetics Inc (GLYC) has net assets worth $3.38 Billion USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.99 Billion) and total liabilities ($2.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GlycoMimetics Inc (GLYC) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.38 Billion |
| % of Total Assets | 56.33% |
| Annual Growth Rate | -3.51% |
| 5-Year Change | -95.86% |
| 10-Year Change | -86.87% |
| Growth Volatility | 445.61 |
GlycoMimetics Inc - Net Assets Trend (2011–2024)
This chart illustrates how GlycoMimetics Inc's net assets have evolved over time, based on quarterly financial data. Also explore GlycoMimetics Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for GlycoMimetics Inc (2011–2024)
The table below shows the annual net assets of GlycoMimetics Inc from 2011 to 2024. For live valuation and market cap data, see GlycoMimetics Inc (GLYC) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.31 Million | -86.17% |
| 2023-12-31 | $38.41 Million | -10.52% |
| 2022-12-31 | $42.93 Million | -47.39% |
| 2021-12-31 | $81.60 Million | -36.36% |
| 2020-12-31 | $128.22 Million | -16.85% |
| 2019-12-31 | $154.20 Million | -24.95% |
| 2018-12-31 | $205.46 Million | +71.65% |
| 2017-12-31 | $119.70 Million | +239.09% |
| 2016-12-31 | $35.30 Million | -12.78% |
| 2015-12-31 | $40.47 Million | -20.34% |
| 2014-12-31 | $50.80 Million | +1647.37% |
| 2013-12-31 | $2.91 Million | -76.79% |
| 2012-12-31 | $12.53 Million | +48.14% |
| 2011-12-31 | $8.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to GlycoMimetics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49430804415500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $64.48K | 0.00% |
| Other Components | $499.68 Billion | 9403.82% |
| Total Equity | $5.31 Billion | 100.00% |
GlycoMimetics Inc Competitors by Market Cap
The table below lists competitors of GlycoMimetics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Puri Global Sukses Tbk Pt
JK:PURI
|
$10.14 Million |
|
Peregrine Gold Ltd
AU:PGD
|
$10.14 Million |
|
Logismos Information Systems S.A
AT:LOGISMOS
|
$10.14 Million |
|
XWELL Inc.
NASDAQ:XWEL
|
$10.15 Million |
|
PT Winner Nusantara Jaya Tbk
JK:WINR
|
$10.12 Million |
|
Intrasense
PA:ALINS
|
$10.11 Million |
|
Intelicanna Ltd
TA:INTL
|
$10.11 Million |
|
Ostin Technology Group Co Ltd
NASDAQ:OST
|
$10.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GlycoMimetics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 38,414,401 to 5,313,562,000, a change of 5,275,147,599 (13732.2%).
- Net loss of 37,879,158 reduced equity.
- Other factors increased equity by 5,313,026,757.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-37.88 Million | -0.71% |
| Other Changes | $5.31 Billion | +99.99% |
| Total Change | $- | 13732.21% |
Book Value vs Market Value Analysis
This analysis compares GlycoMimetics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $7.07 | $0.16 | x |
| 2012-12-31 | $10.47 | $0.16 | x |
| 2013-12-31 | $2.43 | $0.16 | x |
| 2014-12-31 | $2.75 | $0.16 | x |
| 2015-12-31 | $2.13 | $0.16 | x |
| 2016-12-31 | $1.66 | $0.16 | x |
| 2017-12-31 | $4.07 | $0.16 | x |
| 2018-12-31 | $5.01 | $0.16 | x |
| 2019-12-31 | $3.56 | $0.16 | x |
| 2020-12-31 | $2.80 | $0.16 | x |
| 2021-12-31 | $1.59 | $0.16 | x |
| 2022-12-31 | $0.82 | $0.16 | x |
| 2023-12-31 | $0.61 | $0.16 | x |
| 2024-12-31 | $82.41 | $0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GlycoMimetics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (-0.71%) is above the historical average (-76.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -72.29% | -160.29% | 0.13x | 3.42x | $-6.96 Million |
| 2012 | 29.18% | 23.96% | 0.83x | 1.47x | $2.40 Million |
| 2013 | -364.78% | -265.63% | 0.76x | 1.82x | $-10.90 Million |
| 2014 | -21.89% | -74.01% | 0.26x | 1.13x | $-16.20 Million |
| 2015 | -31.55% | -63.62% | 0.41x | 1.20x | $-16.82 Million |
| 2016 | -90.11% | -176722.22% | 0.00x | 1.20x | $-35.34 Million |
| 2017 | -27.80% | 0.00% | 0.00x | 1.07x | $-45.25 Million |
| 2018 | -23.50% | 0.00% | 0.00x | 1.05x | $-68.82 Million |
| 2019 | -35.09% | -601.29% | 0.05x | 1.09x | $-69.54 Million |
| 2020 | -39.21% | -494.68% | 0.07x | 1.11x | $-63.10 Million |
| 2021 | -77.38% | -5443.31% | 0.01x | 1.16x | $-71.30 Million |
| 2022 | -217.40% | -124562.69% | 0.00x | 1.21x | $-97.62 Million |
| 2023 | -96.06% | -368994.20% | 0.00x | 1.18x | $-40.74 Million |
| 2024 | -0.71% | 0.00% | 0.00x | 0.00x | $-569.24 Million |
Industry Comparison
This section compares GlycoMimetics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GlycoMimetics Inc (GLYC) | $3.38 Billion | -72.29% | 0.78x | $10.13 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.